Science Advisory Board

Doug Lauffenburger

Doug Lauffenburger, PhD (SAB Chair)

Ford Professor of Biological Engineering, Chemical Engineering and Biology Linked In

Head of the Department of Biological Engineering, Massachusetts Institute of Technology

Joseph Loscalzo

Joseph Loscalzo, MD,PhD

Chair of the Department of Medicine and Physician-in-Chief at Brigham and Women Hospital (BWH) Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School (HMS)

Werner Meier

Werner Meier

Former Vice President of Biologics Drug Discovery, Biogen, Inc.

Bruce Tidor

Bruce Tidor, PhD

Professor of Biological Engineering and Computer Science, Massachusetts Institute of Technology

Mike Yaffe

Mike Yaffe, MD,PhD

David H. Koch Professor of Biology and Biological Engineering, Massachusetts Institute of Technology, Director of Clinical Outreach, Koch Institute for Integrative Cancer Research Senior Associate Member, Broad Institute Attending Surgeon, Beth Israel Deaconess Medical Center

Board of Directors

Peter Sorger

Peter Sorger, PhD

Otto Krayer Professor of Systems Pharmacology Linked In

Head of the Program in Therapeutic Science, Harvard Medical School.


John M. Burke, PhD

Co-Founder, President, and CEO  Linked In

Dr. Burke BS and MS are in Applied Mathematics from the University of Massachusetts, Lowell, in 1993 and 1995, respectively. His PhD degree is in Applied Mathematics from Arizona State University in 2003. His research interests include singularly and randomly perturbed differential equations, bifurcation theory, and applying dynamical systems theory to study and understand how cells and tissues make decisions in humans, and human disease.

Prior to co-founding Applied BioMath, Dr. Burke joined Boehringer Ingelheim in 2008 as Associate Director, Head of Systems Biology. In 2011, he was promoted to Senior Principal Scientist. At Boehringer Ingelheim, he started, developed and managed the Systems Biology group, portfolio, and strategy. The group was responsible for applying systems techniques to the drug discovery process across all Research sites, and supporting Development and Medicine. Prior to Boehringer Ingelheim, Dr. Burke was at Merrimack Pharmaceuticals, Co-Scientific Director of the Cell Decision Processes Center, Systems Biology Department, HMS, and was a Sr. Postdoctoral Fellow in Douglas A. Lauffenburger lab, Biological Engineering Department, MIT. While at MIT and HMS, Dr. Burke provided consulting or advising for various companies, including AstraZeneca, Pfizer, Momenta, Matlab, and RES Group. Presently he is an on the advisory boards for the MIT

Joshua Apgar

Joshua Apgar, PhD

Co-Founder and CSO Linked In

Before co-founding Applied BioMath Josh was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. His work leveraged physics-based models to: translate in vitro and in vivo data, assess target feasibility, understand drug mechanism of action, and predict human doses. The ultimate goal of this work was to reduce late stage attrition in drug development through a deep and quantitative interrogation of drug pharmacology and disease pathophysiology.

Josh received his PhD from MIT in Biological Engineering where he worked on experiment design for Systems Biology, focusing on the identification of tractable experiments that could allow for the estimation of unknown parameters and reveal complex mechanisms in signal transduction networks. Before that Josh worked at Avaki to develop a highly scalable software platform to support High Performance Computing, and Enterprise Information Integration in the Life Sciences, and Engineering.

Andrew Sutherland

Andrew Sutherland, MSc

Co-Founder and CFO Linked In

Andrew brings over 18 years experience in growing and developing financial and operational processes to Applied BioMath. As one of the co-founders, Andrew is responsible for all business matters of Applied BioMath. He has a long track record of successfully driving shareholder value and most recently was head of finance & administration for Litle & Co., which was acquired by Vantiv in 2012. Prior to Litle, Andrew has worked for a number of startups, all in the finance and administration role. Andrew started his career in large, multi-national companies, most notably GTE Internetworking/Genuity where he worked in Strategic Finance and Mergers & Acquisitions, assisting in Genuity IPO. Andrew received his undergraduate degree from the University of Massachusetts and a Master of Science in International Accounting & Finance from The London School of Economics.

Vihann Kong

Vihann Kong

President and CEO of Allieum Linked In


Design by | Icons by Lokas Software